Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

StreamlineValve

Financiado

Flow Controlled Prosthetic Heart Valves

Prosthetic Heart Valves (HV), both biological (BHV) and mechanical (MHV), have improved the survival rate and the quality of life of valvular heart-disease patients over the last six decades. While BHVs, taken from animal tissue,... ver más

31/08/2025

TECHNION ISRAEL I...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

TECHNION ISRAEL INSTITUTE OF TECHNOLOGY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-05

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2023-POC: ERC PROOF OF CONCEPT GRANTS

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

TECHNION ISRAEL INSTITUTE O...

150.00K€ | Lider

Proyectos interesantes

BIOMITRAL Engineering the mitral valve bioinspired control of structu... 2M€ Cerrado

LIFELET Business plan optimisation and preparation for scaling of a... 75K€ Cerrado

PID2021-124868OB-C22 STENTS POLIMERICOS ADAPTABLES PARA TRATAR COARTACION AORTICA... 94K€ Cerrado

GrownValve A prosthetic heart valve for adults and children, made from... 4M€ Cerrado

BioChord biomimetic engineered chordae tendineae for valve repair and... 150K€ Cerrado

PRE2018-084392 PROPIEDADES MECANICAS EMERGENTES DE PROTEINAS EN EL MIOCARDI... 93K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 18 meses Fecha Inicio: 2024-02-05
Fecha Fin: 2025-08-31

Líder del proyecto

TECHNION ISRAEL INSTITUTE OF TECHNOLOGY

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Prosthetic Heart Valves (HV), both biological (BHV) and mechanical (MHV), have improved the survival rate and the quality of life of valvular heart-disease patients over the last six decades. While BHVs, taken from animal tissue, show improved hemodynamics, their durability is limited, whereas MHVs can last a patient's entire lifetime but require lifetime anticoagulation medication to reduce thrombotic complications. Future Polymeric HVs (PHV) hold the potential for enhanced durability compared to BHVs, while potentially avoiding the necessity for anticoagulation therapy that MHVs demand. However, the problem of flow-related thrombosis in PHVs remains a critical challenge. Generally, flow-related thrombosis complications can be avoided by altering the flow field around the PHV, such as reducing vortices and circulatory hemodynamic structures as well as decreasing shear stresses which can lead to platelet activation. Inspired by passive flow control in nature and in the aerodynamics industry, where manipulation of fluid flow via a small configuration change provides large engineering benefits in swimming or flying, we aim to use a flow control strategy to optimize blood flow through PHVs. More specifically, in StreamlineValve, we present a new, patented, PHV that is designed to alter the flow field around the valve in a manner that reduces the primary factors contributing to coagulation on PHVs. We have already successfully demonstrated this concept in vitro in a modified MHV. In this PoC, we propose to extend this to the future of prosthetic valves via a flow controlled PHV that can be implanted via a simple transcatheter procedure avoiding undesired surgical procedures. Altogether, StreamlineValve represents a paradigm shift in the realm of prosthetic HVs, offering the potential to enhance valve longevity, quality of life, and patient safety.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores